No Detail Found!

Safety and efficay of repaglinide compared with glibenclamide in the management of type 2 diabetic Pakistani patients.

Author(s)
Rushd Jibran Punjab Instutute of Cardiology, Lahore, Pakistan
M. Suliman lmran Women Medical College, Abbottabad, Pakistan
Fayyaz Qureshi Women Medical College, Abbottabad, Pakistan
Masood Ahmed Women Medical College, Abbottabad, Pakistan
Abstract
To evaluate the safety and efficacy (glycemic control) provided by repaglinide compared with glibenclamide in newly diagnosed type 2 (non-insulin dependant) diabetic patients. Diabetic clinic in medical outdoor of Mayo Hospital, Lahore. Randomized prospective study. This single center study of one year duration was carried out in 100 patients between 30-70 years, all diagnosed to have type 2 diabetes mellitus recently and were not on any treatment. They were randomly categorized into two groups, repaglinide (test) and glibenclamide (control) groups. The study consisted of an initial induction day followed by follow-up visits after every fortnight. Repaglinide was given pre-parandial up to three times a day and glibenclamide was administered once or twice daily. Dosage was adjusted after every visit according to blood glucose level. Fasting blood glucose level, two hours postparandial blood glucose, weight and blood pressure were recorded on every visit, while glycosylated hemoglobin (HbAlc) was estimated thrice during the study (at the beginning, at six months and at the end of one year). Of the hundred randomized patients (50 in each groups), all showed a decrease in fasting blood glucose level, two hours postparandial blood glucose and HbAlc. Mean reduction in fasting blood glucose in repaglinide group was 64+53 mg/dl and those by glibenclamide group was 34.7+53 (P=0.007). The mean reduction in two hours postprandial blood glucose was 119+66 in repaglinide group, while 87.6+74 was observed in glibenclamide group (P=0.02).HbAlc mean reduction in both repaglinide and glibenclamide groups was 1.1+0.3 and 0.7+0.5 respectively (P=0.00). No statistically significant weight change was observed and no hypoglycemic events were recorded in both the groups. The results suggest that repaglinide and glibenclamide both were effective in lowering fasting glucose level, two hours postparandial blood glucose level and HbAlc if used regularly for one year. The effect of repaglinide in lowering HbAlc was impressive as compared to glibenclamide. Both the drugs were well tolerated and weight change was minimal in both the groups.
Publication Details
Page(s) 385-390
DOI DOI not available
Published Journal: Pakistan Journal of Medical Sciences, Volume: 22, Issue: 4, Year: 2006

Request the full text from PASTIC

0

Citations

0

Downloads

59

Views